VERTEX PHARMACEUTICALS INC / MA Operating Lease Right-of-Use Assets
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Operating Lease Right-of-Use Assets of $1.66 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.66B.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.69B.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.56B.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.59B.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $1.66B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.69B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.56B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.59B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.31B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.34B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.36B 10-K · filed 2026-02-13 | |
| 2024-09-30 | $1.40B 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $569.80M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $312.90M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $293.60M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $310.50M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $324.30M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $336.30M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $347.40M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $342.70M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $318.30M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $329.00M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $330.30M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $312.34M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $316.87M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $322.32M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $325.60M 10-K · filed 2022-02-09 | $325.56M 10-K · filed 2021-02-11 |
| 2020-09-30 | $256.80M 10-Q · filed 2020-10-30 | |
| 2019-12-31 | $88.20M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $60.93M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $58.03M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $60.57M 10-Q · filed 2019-05-01 | |
| 2019-01-01 | $61.67M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |